20Med NP platform
At 20Med Therapeutics, we develop RNA and DNA based vaccines and therapeutics based on proprietary bio-responsive polymeric Nanoparticles.
In developing thermostable vaccines for infectious diseases, we aim to tackle the inequitable global distribution of medical innovations.
In addition, our polymeric Nanoparticle platform is being applied to the development of several vaccines and therapeutics for human and animal health indications to help accelerate partnered programs toward clinical trials.
Our technology addresses the limitations of other delivery technologies
We offer distinct advantages:
Rapid development – ready-to-use delivery platform for rapid development of new vaccines and adjustments to existing ones; same composition of 20Med polymeric Nanoparticles for all payloads.
Ease of manufacture – accessible starting materials, scalable, one step loading and formulation in absence of solvents.
No loss of RNA/DNA – no purification step needed after formulation and therefore no loss of RNA/DNA.
Stable formulation – loaded 20Med Nanoparticles can be stored in solution at lower temperatures or at room temperature as a lyophilized product; partnership agreement with Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of our delivery technology in a project that aims to store the product at 2-8 degrees with no need for frozen storage.
Unique IP position – composition of matter patents granted worldwide; independent of complex IP landscape of lipid nanoparticles.